retatrutide glp-1 gip glucagon triple agonist 40mg The TRIUMPH-1 Phase 3 results
Description
Zhang, J., Cai, W., Liu, D., Zheng, N., Wang, Y., Qiu, F., Zheng, H., Gan, H., Huang, Y., Zhou, Y., Yu, M., Xiong, S., Luo, G., Guo, J., Zhu, L., Zhang, Y., Ke, H., Liu, Y., Huang, G., Yu, C., Xu, J
EMPEROR-Reduced included 1,188 (64%) patients treated with JARDIANCE 65 years of age and older, and 503 (27%) patients 75 years of age and older
are or were previously employees and stockholders of Amgen
The effects of pharmaceutical and non-pharmaceutical treatments on bone outcomes such as BTMs and/or BMD are warranted
10.1111/dom.13172 67 WangY.ParlevlietE
